An interview with Alan Stitt about research in the AMD field.
Jean Feyen, PhD., Chief Scientific Officer, and Andy De Deene, M.D., Global Head of Development, explain why Oxurion decided to focus on non-VEGF pathways.
Age-related macular degeneration (or AMD) is the leading cause of blindness. At Oxurion, we’re discovering new ways to treat both forms.